Spencer Rand, Fisher Steven, Lewis Geoffrey P, Malone Terri
Texas Retina Associates, Dallas, TX, USA.
Molecular, Cellular, and Developmental Biology.
Clin Ophthalmol. 2017 Oct 6;11:1797-1803. doi: 10.2147/OPTH.S140218. eCollection 2017.
A 70-year-old woman with retinitis pigmentosa experienced an epiretinal membrane (ERM) formation and a tractional retinal detachment (RD) following subretinal administration of palucorcel (CNTO 2476), a novel human umbilical tissue-derived cell-based therapy, as part of a Phase I study. The clinical course and results of a histologic examination of the ERM, which was peeled during surgery to repair the RD, are described here.
In this open-label, first-in-human, Phase I study (NCT00458575), two of seven subjects developed RD, with an ERM formation reported in a woman receiving a targeted dose of 3.0×10 palucorcel administered via a transvitreal route. A sample of the ERM was retained for analysis following the ERM peeling procedure. Clinical outcomes and ERM histology, based on immunocytochemistry analyses and fluorescence in situ hybridization (FISH) staining, were evaluated.
We first noted the RD and formation of the ERM at 26 days after palucorcel administration. The ERM was cellular and contained multiple cell types, including Müller glial cells, immune cells, neurites, retinal pigment epithelial cells, and palucorcel. The majority of cells were not actively dividing. FISH staining showed a subset of Y chromosome-positive cells in the ERM from this woman, supporting the presence of palucorcel (derived from umbilical cord tissue of male neonate). Palucorcel did not differentiate into Müller glia, immune cells, neurites, or retinal pigment epithelial cells.
The development of an ERM containing both subject (self) cells and palucorcel suggests that palucorcel egress in the vitreal cavity after retinotomy may contribute to ERM formation and RD and that an alternative delivery method will be required before further studies are conducted. Subsequent clinical research using alternative subretinal delivery methods for palucorcel in other indications suggests that membrane development does not occur when palucorcel is delivered without retinal perforation.
一名70岁患有色素性视网膜炎的女性在接受新型人脐组织源细胞疗法帕卢科尔(CNTO 2476)视网膜下给药后,作为I期研究的一部分,发生了视网膜前膜(ERM)形成和牵拉性视网膜脱离(RD)。本文描述了手术修复RD时剥除的ERM的临床病程及组织学检查结果。
在这项开放标签、首例人体I期研究(NCT00458575)中,7名受试者中有2名发生了RD,一名接受经玻璃体途径给予目标剂量3.0×10帕卢科尔的女性报告出现了ERM形成。ERM剥除术后保留了一份ERM样本用于分析。基于免疫细胞化学分析和荧光原位杂交(FISH)染色,对临床结果和ERM组织学进行了评估。
我们在帕卢科尔给药后26天首次注意到RD和ERM形成。ERM是细胞性的,包含多种细胞类型,包括Müller胶质细胞、免疫细胞、神经突、视网膜色素上皮细胞和帕卢科尔。大多数细胞未处于活跃分裂状态。FISH染色显示该女性的ERM中有一部分Y染色体阳性细胞,支持了帕卢科尔(源自男性新生儿脐带组织)的存在。帕卢科尔未分化为Müller胶质细胞、免疫细胞、神经突或视网膜色素上皮细胞。
含有受试者(自身)细胞和帕卢科尔的ERM的形成表明,视网膜切开术后帕卢科尔在玻璃体腔中的逸出可能促成ERM形成和RD,并且在进行进一步研究之前需要一种替代给药方法。随后在其他适应症中使用替代视网膜下给药方法给予帕卢科尔的临床研究表明,在无视网膜穿孔的情况下给予帕卢科尔时不会发生膜形成。